Merck & Co. Inc. (MRK) Initiates Phase 3 Trial on Breast Cancer Drug

Merck & Co., Inc. (NYSE:MRK) is one of the cheap blue-chip stocks to invest in now. On August 27, the company confirmed it has initiated the HERTHENA-Breast04 phase 3 clinical trials in partnership with Daiichi Sankyo.

Merck & Co. Inc. (MRK) Initiates Phase 3 Trial on Breast Cancer Drug

Dosing of the first patient with patritumab deruxtecan for metastatic hormone receptor-positive, HER2-negative breast cancer has already started. The randomized trial is to evaluate patritumab deruxtecan against the physician’s choice of treatment in patients with an advanced metastatic cancer.

The trial aims to enroll 1,000 patients across Asia, Europe, North America, and South America. Its dual primary endpoints are progression-free survival, as determined by blinded independent central review, and overall survival.

In 2023, Merck entered into a collaboration agreement with Daiichi Sankyo to jointly develop and commercialize patritumab deruxtecan and other antibody drug conjugates.

Merck & Co., Inc. (NYSE:MRK) is a global science and technology company that operates in three main business areas: Healthcare, focusing on developing innovative therapies for diseases; Life Science, providing tools and services for scientific research and biotech production; and Electronics, creating materials for the semiconductor and display industries.

While we acknowledge the potential of MRK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRK and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Robinhood Stocks to Buy Right Now and 13 Best Long-Term Stocks to Invest in According to Warren Buffett.

Disclosure: None. This article is originally published at Insider Monkey.